Immunitybio Inc IBRX

Healthcare Biotechnology

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

NDAQ:IBRX - Post by User

Immunitybio Inc

<< Previous

Bullboard Posts

Post by whytestockson Jul 07, 2024 2:15am

206 Views

Post# 36121594

Objective long/short (IBRX) Report

BREAKING NEWS: $IBRX Objective long/short (IBRX) Report2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...IBRX - Objective long/short (IBRX) Report

<< Previous

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario